Exodus Point Capital Management, LP Catalyst Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$14.34 - $21.05 $1.74 Million - $2.55 Million	121,122 New	121,122 $2.01 Million
Q3 2022 Nov 10, 2022	SELL	$7.06 - $15.52 $1.44 Million - $3.17 Million	-203,993 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$6.23 - $8.57 $1.14 Million - $1.56 Million	182,242 Added 837.86%	203,993 $1.43 Million
Q1 2022 May 13, 2022	SELL	$5.31 - $8.31 $210,084 - $328,776	-39,564 Reduced 64.53%	21,751 $180,000
Q4 2021 Feb 11, 2022	SELL	$5.21 - $7.45 $53,110 - $75,945	-10,194 Reduced 14.26%	61,315 $415,000
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $219,176 - $272,953	45,191 Added 171.71%	71,509 $379,000
Q2 2021 Aug 16, 2021	BUY	$4.29 - $6.05 $112,904 - $159,223	26,318 New	26,318 $151,000
Q1 2021 May 17, 2021	SELL	$3.45 - $4.69 $144,303 - $196,168	-41,827 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.97 - $3.83 $124,226 - $160,197	41,827 New	41,827 $140,000
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $30,397 - $51,993	-10,235 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.48 - $5.05 $35,617 - $51,686	10,235 New	10,235 $47,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.